Background: The diagnosis of drug hypersensitivity reactions (DHRs) is based both on clinical history and in vivo tests, such as specific IgE and cutaneous tests, when available. Objectives: The aim of this work was to evaluate the basophil activation test (BAT) as a supplementary tool for drug challenges and drug allergy diagnosis. Method: We evaluated 204 outpatients reporting DHRs. Available serum-specific IgE drugs were determined and cutaneous tests were performed when appropriate. BAT was performed immediately after blood sampling. The expression of CD63 was evaluated with flow cytometry. The test was considered positive when CD63 expression was > 5% and the stimulation index (the ratio of the percentage of CD63-expressing cells with drug exposure/percentage of CD63-expressing cells with wash buffer) was > 2. Patients who reported mild to severe reactions and those with a discrepancy between clinical history and BAT underwent a challenge test. Results: The drugs that caused adverse reactions were mainly antibiotics (49%). Non-steroid anti-inflammatory drugs (NSAID) were cited as responsible for DHRs in 37%, with the remaining 14% being due to other drugs. BAT revealed a high specificity (92%) and low sensitivity for antibiotics (40%). For the suspected reactions to penicillin, both the in vitro tests supported 94% of the diagnoses. We also observed a high specificity in the case of challenge with NSAIDs (100% specificity). Conclusions: BAT is effective in discriminating adverse drug reactions, whilst only more critical cases require integrated evaluations and more complex clinical examinations. It is relevant that the concordance of anamnesis and in vitro tests reduce the need for challenge testing, limiting them to selected cases.

Keywords:
Drug allergy, Basophil activation test, Penicillins, β-Lactams
1.
World Health Organization: International drug monitoring: the role of national centres. Technical Report Series No. 498. Geneva, WHO, 1972.
2.
Gomes ER, Demoly P: Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5: 309–316.
3.
Limsuwan T, Demoly P: Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock). Med Clin North Am 2010; 94: 691–710.
4.
Blanca M, Romano A, Torres MJ, et al: Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009; 64: 183–193.
5.
Demoly P, Adkinson NF, Brockow K, et al: International consensus on drug allergy. Allergy 2014; 69: 420–437.
6.
Chiriac AM, Demoly P: Drug allergy diagnosis. Immunol Allergy Clin N Am 2014; 34: 461– 471.
7.
Dubini M, Marraccini P, Pignatti P: Multiple drug allergy: a case of anaphylaxis to levofloxacin but tolerance to ciprofloxacin. Ann Allergy Asthma Immunol 2016; 116: 465.
8.
World Medical Association: Declaration of Helsinki: ethical principles for medical research involving human subjects. Helsinki, WMA, 1964.
9.
Pignatti P, Yacoub MR, Testoni C, et al: Evaluation of basophil activation test in suspected food hypersensitivity. Cytometry B Clin Cytom 2017; 92: 279–285.
10.
Sanz ML, Gamboa PM, Antépara I, et al: Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. Clin Exp Allergy 2002; 32: 277–286.
11.
Defrance C, Bousquet PJ, Demoly P: Evaluating the negative predictive value of provocation tests with nonsteroidal anti-infammatory drugs. Allergy 2011; 66: 1410–1414.
12.
Ring J, Messmer K: Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 26: 466–469.
13.
Brockow K, Przybilla B, Aberer W, et al: Guideline for the diagnosis of drug hypersensitivity reactions. Allergo J Int 2015; 24: 94–105.
14.
Gomes E, Cardoso MF, Praca F, et al: Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy 2004; 34: 1597–1601.
15.
Cornejo-Garcia JA, Oussalah A, Blanca M, et al: Genetic predictors of drug hypersensitivity. Curr Pharm Des 2016; 22: 6725–6733.
16.
Alhawassi TM, Krass I, Bajorek BV, Pont LG: A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging 2014: 9 2079–2086.
17.
Ma J, Wang Y, Gao M, Meng Q, Liu J: Adverse drug reactions as the cause of emergency department admission of patients aged 80 years and older. Eur J Intern Med 2012; 23:e162–e163.
18.
Gor AP, Saksena M: Adverse drug reactions of nonsteroidal anti-inflammatory drugs in orthopedic patients. J Pharmacol Pharmacother 2011; 2: 26–29.
19.
AIFA: Agenzia Italiana del Farmaco. http://www.aifa.gov.it/.
20.
Chiriac AM, Demoly P: Multiple drug hypersensitivity syndrome. Curr Opin Allergy Clin Immunol 2013; 13: 323–329.
21.
Mittmann N, Knowles SR, Gomez M, et al: Evaluation of the extent of underreporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf 2004; 27: 477–487.
22.
Messaad D, Sahla H, Benahmed S, et al: Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004; 140: 1001–1006.
23.
Sanz ML, Gamboa PM, Mayorga C: Basophil activation tests in the evaluation of immediate drug hypersensitivity. Curr Opin Allergy Clin Immunol 2009; 9: 298–304.
24.
Ebo DG, Bridts CH, Hagendorens MM, et al: Basophil activation test by flow cytometry: present and future applications in allergology. Cytometry B Clin Cytom 2008; 74: 201–210.
25.
Romano A, Demoly P: Recent advances in the diagnosis of drug allergy. Curr Opin Allergy Clin Immunol 2007; 7: 299–303.
26.
de Weck AL, Sanz ML, Gamboa PM, Aberer W, Bienvenu J, et al: Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. Int Arch Allergy Immunol 2008; 146: 177–189.
27.
Rubio M, Bousquet PJ, Gomes E, Romano A, Demoly P: Results of drug hypersensitivity evaluations in a large group of children and adults. Clin Exp Allergy 2012; 42: 123–130.
28.
Kowalski ML, Makowska JS, Blanca M, et al: Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy 2011; 66: 818–829.
29.
Bousquet PJ, Pipet A, Bousquet-Rouanet L, Demoly P: Oral challenges are needed in the diagnosis of β-lactam hypersensitivity. Clin Exp Allergy 2008; 38: 185–190.
30.
Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J, Vultaggio A, et al: In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2016; 71: 1103–1134.
31.
Ebo DG, Sainte-Laudy J, Bridts CH, et al: Flow-assisted allergy diagnosis: current applications and future perspectives. Allergy 2006; 61: 1028–1039.
32.
Scott I, Jayathissa S: Quality of drug prescribing in older patients: is there a problem and can we improve it? Intern Med J 2010; 40: 7–18.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.